Search Page

1

Cite

Share

Why are Behçet's disease patients always exhausted?

Senusi AA, Liu J, Bevec D, Bergmeier LA, Stanford M, Kidd D, Jawad A, Higgins S, Fortune F. Senusi AA, et al. Among authors: bevec d. Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):53-62. Epub 2018 Oct 5. Clin Exp Rheumatol. 2018. PMID: 30299243 Free article.

Cite

Share

2

Cite

Share

Eukaryotic initiation factor 5A activity and HIV-1 Rev function.

Bevec D, Hauber J. Bevec D, et al. Biol Signals. 1997 May-Jun;6(3):124-33. doi: 10.1159/000109118. Biol Signals. 1997. PMID: 9285095 Review.

Cite

Share

3

Cite

Share

Inhalation of vasoactive intestinal peptide in pulmonary hypertension.

Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J. Leuchte HH, et al. Among authors: bevec d. Eur Respir J. 2008 Nov;32(5):1289-94. doi: 10.1183/09031936.00050008. Eur Respir J. 2008. PMID: 18978135 Free article.

Cite

Share

4

Cite

Share

Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.

Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, Rensing-Ehl A, Bacher G, Cavalli V, Bevec D, Delgado M, Müller-Quernheim J. Prasse A, et al. Among authors: bevec d. Am J Respir Crit Care Med. 2010 Aug 15;182(4):540-8. doi: 10.1164/rccm.200909-1451OC. Epub 2010 May 4. Am J Respir Crit Care Med. 2010. PMID: 20442436 Clinical Trial.

Cite

Share

5

Cite

Share

Preserved pulmonary vasodilative properties of aerosolized brain natriuretic peptide.

Leuchte HH, Michalek J, Soenmez O, Meis T, Haziraj S, Cavalli V, Bevec D, Behr J. Leuchte HH, et al. Among authors: bevec d. Pulm Pharmacol Ther. 2009 Dec;22(6):548-53. doi: 10.1016/j.pupt.2009.07.002. Epub 2009 Jul 29. Pulm Pharmacol Ther. 2009. PMID: 19646544

Cite

Share

6

Cite

Share

Screening assay for the identification of deoxyhypusine synthase inhibitors.

Sommer MN, Bevec D, Klebl B, Flicke B, Hölscher K, Freudenreich T, Hauber I, Hauber J, Mett H. Sommer MN, et al. Among authors: bevec d. J Biomol Screen. 2004 Aug;9(5):434-8. doi: 10.1177/1087057104264031. J Biomol Screen. 2004. PMID: 15296643

Cite

Share

7

Cite

Share

The genomic structure encoding human initiation factor eIF-5A.

Koettnitz K, Kappel B, Baumruker T, Hauber J, Bevec D. Koettnitz K, et al. Among authors: bevec d. Gene. 1994 Jul 8;144(2):249-52. doi: 10.1016/0378-1119(94)90385-9. Gene. 1994. PMID: 7545941

Cite

Share

8

Cite

Share

Inhibition of multidrug-resistant HIV-1 by interference with cellular S-adenosylmethionine decarboxylase activity.

Schäfer B, Hauber I, Bunk A, Heukeshoven J, Düsedau A, Bevec D, Hauber J. Schäfer B, et al. Among authors: bevec d. J Infect Dis. 2006 Sep 15;194(6):740-50. doi: 10.1086/507043. Epub 2006 Aug 17. J Infect Dis. 2006. PMID: 16941339

Cite

Share

9

Cite

Share

Graph theory enables drug repurposing--how a mathematical model can drive the discovery of hidden mechanisms of action.

Gramatica R, Di Matteo T, Giorgetti S, Barbiani M, Bevec D, Aste T. Gramatica R, et al. Among authors: bevec d. PLoS One. 2014 Jan 9;9(1):e84912. doi: 10.1371/journal.pone.0084912. eCollection 2014. PLoS One. 2014. PMID: 24416311 Free PMC article.

Cite

Share

10

Cite

Share

New furin inhibitors based on weakly basic amidinohydrazones.

Sielaff F, Than ME, Bevec D, Lindberg I, Steinmetzer T. Sielaff F, et al. Among authors: bevec d. Bioorg Med Chem Lett. 2011 Jan 15;21(2):836-40. doi: 10.1016/j.bmcl.2010.11.092. Epub 2010 Nov 25. Bioorg Med Chem Lett. 2011. PMID: 21168329 Free PMC article.

Cite

Share